Similar articles for PMID: 33277397

Year	Number of Results
2002	1
2003	2
2006	1
2007	4
2008	3
2009	2
2010	1
2011	2
2012	1
2013	6
2014	5
2015	9
2016	8
2017	7
2018	10
2019	16
2020	21
2021	16

1

FAPI PET/CT: Will It End the Hegemony of ¹⁸F-FDG in Oncology?

Hicks RJ, Roselt PJ, Kallur KG, Tothill RW, Mileshkin L. Hicks RJ, et al. J Nucl Med. 2021 Mar;62(3):296-302. doi: 10.2967/jnumed.120.256271. Epub 2020 Dec 4. J Nucl Med. 2021. PMID: 33277397

2

More advantages in detecting bone and soft tissue metastases from prostate cancer using ¹⁸F-PSMA PET/CT.

Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE. Pianou NK, et al. Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7. Hell J Nucl Med. 2019. PMID: 30843003 Free article.

3

⁶⁸Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers.

Giesel FL, Kratochwil C, Lindner T, Marschalek MM, Loktev A, Lehnert W, Debus J, Jäger D, Flechsig P, Altmann A, Mier W, Haberkorn U. Giesel FL, et al. J Nucl Med. 2019 Mar;60(3):386-392. doi: 10.2967/jnumed.118.215913. Epub 2018 Aug 2. J Nucl Med. 2019. PMID: 30072500 Free PMC article.

4

Biodistribution, pharmacokinetics, dosimetry of [⁶⁸Ga]Ga-DOTA.SA.FAPi, and the head-to-head comparison with [¹⁸F]F-FDG PET/CT in patients with various cancers.

Ballal S, Yadav MP, Moon ES, Kramer VS, Roesch F, Kumari S, Tripathi M, ArunRaj ST, Sarswat S, Bal C. Ballal S, et al. Eur J Nucl Med Mol Imaging. 2020 Nov 26. doi: 10.1007/s00259-020-05132-y. Online ahead of print. Eur J Nucl Med Mol Imaging. 2020. PMID: 33244617

5

Abass Alavi: A giant in Nuclear Medicine turns 80 and is still going strong!

Høilund-Carlsen PF. Høilund-Carlsen PF. Hell J Nucl Med. 2018 Jan-Apr;21(1):85-87. doi: 10.1967/s002449910713. Epub 2018 Mar 20. Hell J Nucl Med. 2018. PMID: 29550853 Free article.

6

Improved cancer detection in Waldeyer's tonsillar ring by ⁶⁸Ga-FAPI PET/CT imaging.

Serfling S, Zhi Y, Schirbel A, Lindner T, Meyer T, Gerhard-Hartmann E, Lapa C, Hagen R, Hackenberg S, Buck AK, Scherzad A. Serfling S, et al. Eur J Nucl Med Mol Imaging. 2021 Apr;48(4):1178-1187. doi: 10.1007/s00259-020-05055-8. Epub 2020 Oct 15. Eur J Nucl Med Mol Imaging. 2021. PMID: 33057927

7

Fibroblast Activation Protein-Targeted PET/CT with ⁶⁸Ga-FAPI for Imaging IgG4-Related Disease: Comparison to ¹⁸F-FDG PET/CT.

Luo Y, Pan Q, Yang H, Peng L, Zhang W, Li F. Luo Y, et al. J Nucl Med. 2021 Feb;62(2):266-271. doi: 10.2967/jnumed.120.244723. Epub 2020 Jun 8. J Nucl Med. 2021. PMID: 32513902

8

Targeting Fibroblast Activation Protein: Radiosynthesis and Preclinical Evaluation of an ¹⁸F-Labeled FAP Inhibitor.

Toms J, Kogler J, Maschauer S, Daniel C, Schmidkonz C, Kuwert T, Prante O. Toms J, et al. J Nucl Med. 2020 Dec;61(12):1806-1813. doi: 10.2967/jnumed.120.242958. Epub 2020 Apr 24. J Nucl Med. 2020. PMID: 32332144

9

Role of [⁶⁸Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of peritoneal carcinomatosis and comparison with [¹⁸F]-FDG PET/CT.

Zhao L, Pang Y, Luo Z, Fu K, Yang T, Zhao L, Sun L, Wu H, Lin Q, Chen H. Zhao L, et al. Eur J Nucl Med Mol Imaging. 2021 Jan 7. doi: 10.1007/s00259-020-05146-6. Online ahead of print. Eur J Nucl Med Mol Imaging. 2021. PMID: 33415432

10

Imaging fibroblast activation protein in liver cancer: a single-center post hoc retrospective analysis to compare [⁶⁸Ga]Ga-FAPI-04 PET/CT versus MRI and [¹⁸F]-FDG PET/CT.

Guo W, Pang Y, Yao L, Zhao L, Fan C, Ke J, Guo P, Hao B, Fu H, Xie C, Lin Q, Wu H, Sun L, Chen H. Guo W, et al. Eur J Nucl Med Mol Imaging. 2020 Nov 11. doi: 10.1007/s00259-020-05095-0. Online ahead of print. Eur J Nucl Med Mol Imaging. 2020. PMID: 33179149

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed